Evidence map›Paper›PMID 41638199›Full record

ArticleCell reports. Medicine2026

Proteomics landscape of early T-cell precursor acute lymphoblastic leukemia reveals deficient oxidative phosphorylation signatures.

Miaomiao Liu, Tianyi Chen, Xiangjie Lin, Bowen Wu, Fujie Shi, Junya Liu, Yi Chen, Tao Zeng, Shangyu Hou, Qingfei Pan and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Miaomiao LiuState Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
Tianyi ChenState Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
Xiangjie LinDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, P.R. China; Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, Zhejiang 310003, P.R. China.
Bowen WuDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, P.R. China; Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, Zhejiang 310003, P.R. China.
Fujie ShiState Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
Junya LiuState Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
Yi ChenDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, P.R. China; Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, Zhejiang 310003, P.R. China.
Tao ZengBiomedical Big Data Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China; Zhejiang University Cancer Center, Zhejiang University, Hangzhou, China.
Shangyu HouState Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
Qingfei PanDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Xuemei WangState Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
Yiyi YaoDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, P.R. China; Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, Zhejiang 310003, P.R. China.
Wenyu YangInstitute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
Yingchi ZhangInstitute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
Jinyan HuangBiomedical Big Data Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China; Zhejiang University Cancer Center, Zhejiang University, Hangzhou, China.
Jie JinDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, P.R. China; Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, Zhejiang 310003, P.R. China; Zhejiang University Cancer Center, Zhejiang University, Hangzhou, China; Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, China. Electronic address: jiej0503@zju.edu.cn.
Yinghui ZhuState Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China. Electronic address: zhuyinghui@tongji.edu.cn.
Huafeng WangDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, P.R. China; Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, Zhejiang 310003, P.R. China; Zhejiang University Cancer Center, Zhejiang University, Hangzhou, China; Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, China. Electronic address: 1509036@zju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) represents a therapeutically challenging, high-risk leukemia subtype whose comprehensive proteomic characterization remains limited. Our integrated 4D label-free proteomic analysis delineates a distinct molecular signature featuring profound oxidative phosphorylation (OxPhos) deficiency, characterized by compromised mitochondrial ATP synthesis and significant reductions in electron transport chain complexes I and IV. Single-cell RNA sequencing validation establishes that stem-like ETP-ALL populations exhibit substantially diminished ETC activity relative to T-lineage-differentiated counterparts. Pharmacological intervention using dichloroacetate to restore OxPhos functionality effectively suppresses leukemic proliferation and xenograft engraftment through ROS-mediated endoplasmic reticulum stress activation. Furthermore, we identify CD109 as an attractive immunophenotypic marker that not only distinguishes ETP-ALL from other hematologic malignancies but also defines a subset with enhanced ETC suppression and heightened metabolic vulnerability to dichloroacetate. These findings elucidate the mechanistic basis of mitochondrial dysregulation in ETP-ALL pathogenesis and nominate CD109 as a promising biomarker for targeted therapeutic strategies.

Indexed as

Oxidative PhosphorylationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaProteomicsAnimalsAntigens, CDCell ProliferationDichloroacetic AcidHumansMiceMitochondriaAntigens, CDDichloroacetic AcidCD109early T-cell precursor acute lymphoblastic leukemiamitochondrial dysfunctionoxidative phosphorylationproteomics

Identifiers

PMID41638199
PMCPMC12923956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.